Cardioprotection by ε-protein kinase C activation from ischemia: Continuous delivery and antiarrhythmic effect of an ε-protein kinase C-activating peptide

Circulation

Volumn 111, Issue 1, 2005, Pages 44-50

  Inagaki, Koichi ^a   Begley, Rebecca ^a   Ikeno, Fumiaki ^b   Mochly Rosen, Daria ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Arrhythmia; Ischemia; Ischemic preconditioning; Peptides; Protein kinase C

Indexed keywords

PROTEIN KINASE C EPSILON; PROTEIN KINASE C EPSILON ACTIVATING PEPTIDE; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; CARDIOTONIC AGENT; HIS ASP ALA PRO ILE GLY TYR ASP; HIS-ASP-ALA-PRO-ILE-GLY-TYR-ASP; OLIGOPEPTIDE; PEPTIDE FRAGMENT; PRKCE PROTEIN, MOUSE; PROTEIN KINASE C; TAT PROTEIN (47 57), HIV 1; TAT PROTEIN (47-57), HIV-1; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DESENSITIZATION; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVATION; EX VIVO STUDY; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; IN VIVO STUDY; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SWINE; TOXICITY TESTING; ANIMAL; CORONARY BLOOD VESSEL; DRUG SCREENING; ENZYME INDUCTION; ENZYMOLOGY; FEMALE; HEART INFARCTION; INFUSION PUMP; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOUSE; PATHOLOGY; PROTEIN TRANSPORT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; CORONARY VESSELS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; GENE PRODUCTS, TAT; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAPERITONEAL; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; PROTEIN TRANSPORT; SUS SCROFA; VENTRICULAR FIBRILLATION;

EID: 11244310899     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000151614.22282.F1     Document Type: Article

References (31)

1. Gray MO, Karliner JS, Mochly-Rosen D. A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem. 1997;272:30945-30951.
2. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 1997;81:404-414.
3. Mitchell MB, Meng X, Ao L, Brown JM, Harken AH, Banerjee A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res. 1995;76:73-81.
4. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GWII, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and ε PKC. Proc Natl Acad Sci USA. 2001;98:11114-11119.
5. Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. Protein kinase C-ε is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol. 1999;31:1937-1948.
6. Dorn GW II, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation. Proc Natl Acad Sci U S A. 1999;96:12798-12803.
7. Nakano A, Cohen MV, Downey JM. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther. 2000;86:263-275.
8. Inagaki K, Hahn HS, Dorn GWII, Mochly-Rosen D. Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator. Circulation. 2003;108:869-875.
9. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective εPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol. 2001;8:1123-1129.
10. Hashimi MW, Thornton JD, Downey JM, Cohen MV. Loss of myocardial protection from ischemic preconditioning following chronic exposure to R(-)-N6-(2-phenylisopropyl)adenosine is related to defect at the adenosine A1 receptor. Mol Cell Biochem. 1998;186:19-25.
11. Tsuchida A, Thompson R, Olsson RA, Downey JM. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. J Mol Cell Cardiol. 1994;26:303-311.
12. Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun. 2004;318:949-954.
13. Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E, Mochly-Rosen D. Inhibition of delta protein kinase C protects against reperfusion injury of the ischemic heart, in vivo. Circulation. 2003;108:2304-2307.
14. Johnson JA, Mochly-Rosen D. Inhibition of the spontaneous rate of contraction of neonatal cardiac myocytes by protein kinase C isozymes: a putative role for the ε isozyme. Circ Res. 1995;76:654-663.
15. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
16. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res. 1994;74:998-1004.
17. Jaken S, Tashjian AH Jr. Blumberg PM. Characterization of phorbol ester receptors and their down-modulation in GH4C1 rat pituitary cells. Cancer Res. 1981;41:2175-2181.
18. Mizuguchi J, Nakabayashi H, Yoshida Y, Huang KP, Uchida T, Sasaki T, Ohno S, Suzuki K. Increased degradation of protein kinase C without diminution of mRNA level after treatment of WEHI-231 B lymphoma cells with phorbol esters. Biochem Biophys Res Commun. 1988;155:1311-1317.
19. Solanki V, Slaga TJ, Callaham M, Huberman E. Down regulation of specific binding of [20-3H]phorbol 12,13-dibutyrate and phorbol ester-induced differentiation of human promyelocytic leukemia cells. Proc Natl Acad Sci USA. 1981;78:1722-1725.
20. Young S, Parker PJ, Ullrich A, Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochem J. 1987;244:775-779.
21. Eto A, Akita Y, Saido TC, Suzuki K, Kawashima S. The role of the calpain-calpastatin system in thyrotropin-releasing hormone-induced selective down-regulation of a protein kinase C isozyme. nPKC ε, in rat pituitary GH4C1 cells. J Biol Chem. 1995;270:25115-25120.
22. Wolfman A, Wingrove TG, Blackshear PJ, Macara IJ. Down-regulation of protein kinase C and of an endogenous 80-kDa substrate in transformed fibroblasts. J Biol Chem. 1987;262:16546-16552.
23. Johnson JA, Adak S, Mochly-Rosen D. Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes. Life Sci. 1995;57:1027-1038.
24. 2003 Heart Disease and Stroke Statistics: 2003 Update. Dallas, Tex: American Heart Association; 2003:1-42.
25. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation. 2002;106:3091-3096.
26. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, McCabe CH, Braunwald E. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998;97:1042-1045.
27. Xiao GQ, Qu Y, Sun ZQ, Mochly-Rosen D, Boutjdir M. Evidence for functional role of εPKC isozyme in the regulation of cardiac Na(+) channels. Am J Physiol Cell Physiol. 2001;281:C1477-86.
28. Xiao GQ, Mochly-Rosen D, Boutjdir M. PKC isozyme selective regulation of cloned human cardiac delayed slow rectifier K current. Biochem Biophys Res Commun. 2003;306:1019-25.
29. Hu K, Mochly-Rosen D, Boutjdir M. Evidence for functional role of εPKC isozyme in the regulation of cardiac Ca(2+) channels. Am J Physiol Heart Circ Physiol. 2000;279:H2658-H2664.
30. Grant AO. Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Pacing Clin Electrophysiol. 1997;20:432-444.
31. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-282. span 'font-family: 'Times New Roman'